热门资讯> 正文

默克宣布Winrevair（Sotatercept）在最近诊断患有肺动脉高压的成年人中进行的3期HyperION研究的总体结果，该研究符合其主要终点，即与安慰剂相比，至临床恶化的时间

2025-06-23 18:48

WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70% of whom were on double background therapy
HYPERION, third Phase 3 study to demonstrate significant efficacy in adults with PAH, was previously stopped early based on review of available data from clinical program

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。